---
document_datetime: 2023-09-21 17:51:25
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/dynepo-epar-procedural-steps-taken-authorisation_en.pdf
document_name: dynepo-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5123688
conversion_datetime: 2025-12-28 15:13:51.64843
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Aventis Pharma S.A. (France) submitted on 31 July 2000 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Dynepo, in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the  Annex  to Council Regulation No (EEC) 2309/93 of 22 July 1993.

•

Medicinal product no longer authorised The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Dr. F. Rotblat Co-Rapporteur: Dr. P. Salmon Licensing status: A new drug application was filed in the following countries: USA (28 July 2000) The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 26 September 2000. · The Rapporteur's first Assessment Report was circulated to all CPMP  members  on 6 December 2000.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP members on 5 December 2000. · During the meeting on 16-17 January 2001 the BWP prepared a Report to the CPMP on the quality issues related to this application. · During  the  meeting  on  23-25  January  2001  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 26 January 2001. · The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 6 July 2001. · The summary report of the inspection carried out at the manufacturing site(s) between 3-6 July 2001 of the Lonza Biologicals (USA) site and between 13-15 June 2001 of the Grupo Lepetit SpA (Italy) site were issued on 24 August 2001 and 27 August 2001 respectively. · The Rapporteur circulated the response Assessment Report on the company's responses to the List of Questions to all CPMP members on 22 August 2001. During  the  meeting  on  11-12  September  2001  the  BWP  prepared  an  Interim  Report  to  the CPMP on the outstanding quality issues related to this application.

- During  the  meeting  on  18-20  September  2001  the  CPMP  agreed  on  the  List  of  outstanding questions to be addressed during an oral explanation. The List of outstanding questions was sent to the applicant on 20 September 2001.
- The company submitted the responses to the List of outstanding questions on 26 September 2001 and 12 November 2001.

<div style=\"page-break-after: always\"></div>

- The Rapporteur circulated  the  Assessment  Report  on  the  company's  responses  to  the  List  of outstanding questions to all CPMP members on 20 November 2001. The Rapporteur indicated that there was no need for an oral explanation.
- The  Rapporteur  circulated  on  30  November  2001  the  final  AR  of  outstanding  issues  arising from the Assessment Report of 19 November 2001.
- During the meeting on 3 -5 December 2001 the BWP prepared the Final Report to the CPMP on the outstanding quality issues related to this application.

<!-- image -->